Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer:: An international phase II study.

被引：0
|
作者：
Rubio, ED
Tabernero, J
van Cutsem, E
Cervantes, A
André, T
Humblet, Y
Soulié, P
Corretgé, S
Kisker, O
de Gramont, A
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Univ Vall Hebron, Barcelona, Spain
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] Hosp Clin Univ, Valencia, Spain
[5] Hop Tenon, F-75970 Paris, France
[6] Clin Univ St Luc, Brussels, Belgium
[7] Ctr Paul Papin, Angers, France
[8] Merck Farma & Quim, Barcelona, Spain
[9] Merck KGaA, Darmstadt, Germany
[10] Hop St Antoine, F-75571 Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254S / 254S
页数：1
相关论文
共 50 条
  • [21] Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase 11 study, OPUS
    Bokernever, C.
    Staroslawska, E.
    Makhson, A.
    Bondarenko, I.
    Hartmann, J. T.
    Shelygin, Y.
    Kolesnik, O.
    Volovat, C.
    Zubel, A.
    Koralewski, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 236 - 236
  • [22] Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial)
    Kotake, Masanori
    Aoyama, Toru
    Munemoto, Yoshinori
    Doden, Kenji
    Kataoka, Masato
    Kobayashi, Kenji
    Nishimura, Genichi
    Fujita, Hidehito
    Nakamura, Keishi
    Takehara, Akira
    Tanaka, Chihiro
    Sakamot, Junichi
    NagatA', Naoki
    Oba, Koji
    Kondo, Ken
    ONCOLOGY LETTERS, 2017, 13 (02) : 747 - 753
  • [23] Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer
    Han, S.
    Park, S.
    Lee, K.
    Song, H.
    Lee, N.
    Lee, K.
    Choi, I
    Lee, M.
    Kim, M.
    Oh, D.
    Im, S.
    Kim, W.
    Bang, Y.
    Kim, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 46 - 46
  • [24] Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer
    Han, S.
    Park, S. R.
    Lee, K.
    Song, H.
    Kim, M. A.
    Oh, D.
    Im, S.
    Kim, W.
    Bang, Y.
    Kim, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] 5-fluorouracil (5-FU),folinic acid (FA) and oxaliplatin (FUFOX) as second chemotherapy in patients with metastatic colorectal cancer (MCRC)
    Andric, Z.
    Murtezani, Z.
    Kovcin, V
    Gutovic, J.
    Kostic, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 67
  • [26] A phase I/II of CPT-11 combined with 5-fluorouracil (5FU)/folinic acid (FA) Nordic schedule as first line therapy in patients (pts) with metastatic colorectal cancer (MCRC).
    Ristamaki, R
    Glimelius, B
    Linne, T
    Pfeiffer, P
    Kjaer, M
    Skovsgaard, T
    Boussard, B
    Oulid-Aissa, D
    Pyrhönen, S
    ANNALS OF ONCOLOGY, 2000, 11 : 47 - 47
  • [27] Oxaliplatin (OXA)/5-fluorouracil (5FU)/folinic acid (FA) in patients (pts) with advanced colorectal cancer (ACRC): Report of an Algerian trial
    Oukkal, M
    Mahfouf, H
    Larbaoui, B
    Djellali, L
    Smail, N
    Benhabyles, B
    Rebaine, M
    Makhloufi, A
    Benouniche, N
    Bouzid, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 304S - 304S
  • [28] A Multicenter Phase II Clinical Study of Oxaliplatin, Folinic Acid, and 5-Fluorouracil Combination Chemotherapy as First-Line Treatment for Advanced Colorectal Cancer: A Japanese Experience
    Baba, Hideo
    Hayashi, Naoko
    Emi, Yasunori
    Kakeji, Yoshihiro
    Egashira, Akinori
    Oki, Eiji
    Shirabe, Ken
    Toyama, Tetsuo
    Ohga, Takefumi
    Yamamoto, Manabu
    Hasegawa, Hirofumi
    Kohakura, Fumiko
    Higashi, Hidefumi
    Niwa, Kiyoshi
    Fujita, Fumihiko
    Ogata, Yutaka
    Kohnoe, Shunji
    Inomata, Masafumi
    Samura, Hironori
    Tokunaga, Shoji
    Maehara, Yoshihiko
    SURGERY TODAY, 2011, 41 (12) : 1610 - 1616
  • [29] A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: A Japanese experience
    Hideo Baba
    Naoko Hayashi
    Yasunori Emi
    Yoshihiro Kakeji
    Akinori Egashira
    Eiji Oki
    Ken Shirabe
    Tetsuo Toyama
    Takefumi Ohga
    Manabu Yamamoto
    Hirofumi Hasegawa
    Fumiko Kohakura
    Hidefumi Higashi
    Kiyoshi Niwa
    Fumihiko Fujita
    Yutaka Ogata
    Shunji Kohnoe
    Masafumi Inomata
    Hironori Samura
    Shoji Tokunaga
    Yoshihiko Maehara
    Surgery Today, 2011, 41 : 1610 - 1616
  • [30] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345